TABLE 1.
Demographic and Clinical Characteristics of PD and Control Subjects
| Characteristic | PD (n = 45) | Control (n = 15) | Statistical significance |
|---|---|---|---|
| Age (y) | 66.3 ± 6.3 | 69.1 ± 8.6 | t = 1.3; P = 0.19 |
| Sex | χ2 = 2.4; P = 0.12 | ||
| Male | 36 | 9 | |
| Female | 9 | 6 | |
| Handedness | χ2 = 0.25; P = 0.62 | ||
| Right | 41 | 13 | |
| Left | 4 | 2 | |
| MoCA | 27.0 ± 2.6 | 27.6 ± 1.8 | t = 0.87; P = 0.39 |
| MDS-UPDRS | |||
| Part I | 5.1 ± 4.5 | ||
| Part II | 5.5 ± 3.5 | ||
| Part III | 34.3 ± 13.2 | ||
| Bradykinesia subscore* | 11.6 ± 5.9 | ||
| Tremor subscore* | 8.8 ± 4.4 | ||
| Rigidity subscore* | 7.5 ± 2.9 | ||
| PIGD subscore* | 2.5 ± 2 | ||
| MDS-UPDRS (I–III) total score | 44.9 ± 16.8 | ||
| Hoehn and Yahr stage | 2.2 ± 0.6 (median, 2.5; range, 1–3) | ||
| Disease duration (y) | 5.8 ± 3.6 | ||
| Levodopa equivalent dose (mg) | 636.6 ± 374.5 |
*Derived from MDS-UPDRS (part III).
MoCA = Montreal cognitive assessment; MDS-UPDRS = Movement Disorder Society revised unified Parkinson disease rating scale; PIGD = postural instability and gait difficulties.